Join the Quest for GCEA and Affordable Innovation at ISPOR 2024 with No Patient Left Behind

BiotechPolicy
Written By Peter Kolchinsky
 

by Richard Xie, Peter Rubin, & Tom Culman

May 3, 2024

There's a transformative shift underway in the realm of healthcare economics and outcomes research (HEOR), and No Patient Left Behind (NPLB) is leading the charge for progress with our multi-stakeholder advisors, members, and research partners. 

Generalized cost-effectiveness analysis (GCEA), a framework to comprehensively assess the societal value of innovative health technologies, will be officially debuted at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in Atlanta this week.

Not familiar with GCEA? Start here!

Will you be at ISPOR? If so, we invite you to embark on an adventure unlike any other: NPLB’s Quest for GCEA and Affordable Innovation. Rest assured, the journey promises a blend of enlightenment and enjoyment (yep, health economists like to party too 😉), all while traversing the treacherous landscape of health economics and policy.

Get GCEA Certified! No magic swords or cursed rings on this quest – instead we’ll be exploring an eclectic collection of conference programs, exhibits, and social events meticulously designed to unite like-minded HEOR professionals. Through this curated experience, you'll delve into the latest work on GCEA and learn how its principles can protect and drive the biotech innovation we hold so dear. You will also gain a renewed perspective on widely accepted beliefs in HEOR and conduct critical assessments of policy instruments to balance affordability with incentives to innovate. 

But wait, there’s more! We are spicing things up with PRIZES. Those who join NPLB’s quest can enter to win cash prizes. Grab a GCEA Quest Passport and collect stamps from each event along the journey, or snap selfies with Quest committee members to participate:

  • Drawing 1: Collect at least 3 stamps and stand a chance to win a $250 Visa gift card.

  • Drawing 2: Complete the entire quest and not only will you be invited to meet with NPLB leadership to shape the future of GCEA and Affordable Innovation, you'll also be entered into a drawing for another $250 Visa gift card!

  • Drawing 3: Even if you can't attend all events, you can still win! Snap a picture with one of our organizing committee members, share it on LinkedIn or X, tag @NPLB_org, and use #GCEA_Quest. Each post counts as an entry into a drawing for a Visa gift card (two winners; each card worth $250).

So, whether you're eager to learn, network, or win some cash, the Quest for GCEA and Affordable Innovation awaits you at ISPOR 2024. Join No Patient Left Behind on this journey and be part of shaping the future of healthcare economics, one stamp at a time.

Visit NPLB’s website to learn more and participate.

Please click here for important RA Capital disclosures.

Peter Kolchinsky

Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Peter also leads the firm’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.

Next

Mariana's acquisition:RAVen, radiopharmaceuticals, and reflections on company-building